FDA Greenlights Clinical Trials for Nexalin’s Insomnia and Anxiety Therapy Headset
The FDA has agreed on the design for Nexalin’s planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
